Mark Albers

Mark Albers is an Assistant Professor of Neurology at Harvard Medical School and a clinician-investigator at Massachusetts General Hospital (MGH), where he directs the Albers Laboratory at the MassGeneral Institute for Neurodegenerative Disease (MIND). His research bridges clinical and basic science, focusing on early detection and therapeutic development for neurodegenerative diseases like Alzheimer’s, ALS, Parkinson’s, and traumatic brain injury through olfactory system studies.

• Education: PhD in Organic Chemistry from Harvard Graduate School of Arts and Sciences (1995), MD from Harvard Medical School (1995).
• Clinical Expertise: Memory and olfactory disorders; practices in the Memory Disorders Unit at MGH.

His lab investigates pathogenic mechanisms of neurodegenerative disease genes using transgenic mouse models, CRISPR screens, multiphoton imaging, and in silico drug trials. Key projects include identifying olfactory deficits as early biomarkers and repurposing FDA-approved drugs for neurodegenerative diseases via the NADALS basket trial. Publications span Alzheimer’s disease, olfactory dysfunction, neuroinflammation, systems pharmacology, and CRISPR technology. Collaborations with the Laboratory of Systems Pharmacology and Harvard Program in Therapeutic Science further his translational goals.